ArticleCurrent protocols2025
Derivatization of Solid Supports Using a Carbamate-Linked Tether Containing a Disulfide Functional Group.
Article in Current protocols, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Derivatization of Solid Supports Using a Carbamate-Linked Tether Containing a Disulfide Functional Group.Current protocols · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemical modifications of oligonucleotides are widely used to improve their functional properties. Amino modifiers provide versatile chemical handles for post-synthetic (bio)conjugation, nucleic acid immobilization on solid supports, and studies of nonenzymatic genome replication related to the origins of life. This protocol describes an economical disulfide-containing solid-support linker that enables on-column synthesis of nucleic acids bearing 3'-amino or 3'-phosphate modifications. The orthogonal nature of this linker allows for an on-column protecting group strategy, facilitating the synthesis of DNA and RNA containing 3'-amino-2',3'-dideoxyribosides from commercially available unprotected mononucleosides. This protocol further extends the on-column construction of oligomers containing 3'-amino-2',3'-dideoxyribosides to those containing a 2'-amino-2'-deoxynucleoside at the 3'-end, using an orthogonal protecting group strategy. An improved on-column deprotection procedure for DNA and RNA is also presented, eliminating the precipitation step typically utilized in conventional RNA workflows, resulting in an enhanced strand recovery for certain sequences. Finally, the disulfide-containing solid support is applied to the preparation of amino acid-oligonucleotide conjugates, wherein the identity of the final product was contingent upon the specific deprotection conditions employed. All oligonucleotide conjugates and derivatives were purified using standard methods [(e.g., strong anion exchange high-performance liquid chromatography (SAX-HPLC)] and characterized by mass spectrometry (MS). © 2025 The Author(s). Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Synthesis of 4,4'-dimethoxytrityl (DMTr) disulfide succinimide and solid-support functionalization reaction Basic Protocol 2: Solid-phase synthesis of DNA containing a 3'-amino-2',3'-dideoxyguanosine using 3'-Disulfide CPG Alternate Protocol 1: Synthesis of DNA containing terminal 2'-amino-2'-deoxyadenosine Alternate Protocol 2: Alternate RNA (terminated with 3'-amino modifiers or phosphate) workflow using D-TentaGel Basic Protocol 3: Amino acid-oligonucleotide conjugate synthesis using Lys and D-TentaGel.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.